NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

National Collaborating Centre for Cancer (UK). The Diagnosis and Treatment of Lung Cancer (Update). Cardiff (UK): National Collaborating Centre for Cancer (UK); 2011 Apr. (NICE Clinical Guidelines, No. 121.)

Cover of The Diagnosis and Treatment of Lung Cancer (Update)

The Diagnosis and Treatment of Lung Cancer (Update).

Show details

Appendix 9.1Members of the Guideline Development Group

Members of the Guideline Development Group (GDG) 2011

GDG Chair
Mr Barrie WhiteNeurosurgeon, Queens Medical Centre, Nottingham
Professor Mark Baker1Divisional Medical Director for Oncology and Surgery and Lead Cancer Clinician, Leeds Teaching Hospitals NHS Trust
GDG Lead Clinician
Dr David BaldwinConsultant Physician, Nottingham University Hospital NHS Trust
Group Members
Barry AttwoodPatient/Carer Representative
Mr Sion BarnardConsultant Thoracic Surgeon, Freeman Hospital, Newcastle-upon-Tyne
Dr Jeremy BraybrookeConsultant Medical Oncologist, University Hospitals Bristol NHS Foundation Trust
Dr Paul CaneConsultant Histopathologist, Guys & St Thomas' NHS Foundation Trust
Dr James EntwisleConsultant Radiologist, Glenfield Hospital, University Hospitals of Leicester NHS Trust
Dr Jesme FoxPatient/Carer Representative, The Roy Castle Lung Cancer Foundation
Thomas HaswellPatient/Carer Representative
Mr Matthew HattonConsultant Clinical Oncologist, Weston Park Hospital, Sheffield
Dana KnoyleMacmillan Lung Cancer Nurse Specialist, Prince Charles Hospital, Cwm Taf Health Board
Dr Richard NealSenior Lecturer in General Practice, North Wales Clinical School, Cardiff University
Mr Richard PageConsultant Thoracic Surgeon, Liverpool Heart and Chest Hospital
Bob ParkDirector, North East London Cancer Network
Sue PascoeLung Cancer Clinical Nurse Specialist, Royal Cornwall Hospital
Dr Michael PeakeConsultant and Senior Lecturer in Respiratory Medicine, Glenfield Hospital, University Hospitals of Leicester NHS Trust
Dr Robert RintoulConsultant Respiratory Physician, Papworth Hospital NHS Foundation Trust, Cambridge
Dr Andrew WilcockMacmillan Clinical Reader in Palliative Medicine and Medical Oncology, Nottingham University Hospitals NHS Trust
Dr Abebaw YohannesReader in Phsiotherapy, Manchester Metropolitan University
1

November 2008 – June 2009

Declarations of interest

The Guideline Development Group were asked to declare any possible conflicts of interest which could interfere with their work on the guideline. The interests that were declared are as follows:

GDG MemberInterest DeclaredType of InterestDecisions Taken
Mark BakerFees from unrestricted educational grantsfor contributions to conferences funded by members of the pharmaceutical industry.Personal pecuniary, non-specificDeclare and can participate in discussions on all topics
Jeremy BraybrookeAmerican Society of Clinical Oncology (ASCO), Orlando (2009), Chicago (2010). Grants to cover travel plus registration and accommodation. Roche and Pfizer respectively.Personal pecuniary, non-specificDeclare and can participate in discussions
Received an honorarium from Boehringer Ingelheim for attending an advisory board on afatinib for second/third line treatment of advanced NSCLC in December 2010.Personal pecuniary, specificDeclare and must withdraw from discussion on all topics that include afatinib until December 20111
Jesme FoxEmployer has received grants from pharmaceutical and commercial businesses. Have also attended conferences and participated in advisory boards organised by pharmaceutical companies. Donations have been given by the company to RCLCF in lieu of timeNon-personal pecuniary, specificDeclare and can participate in discussions on all topics
Tom HaswellGiven media interviews on personal views as a lung cancer patient.Personal non-pecuniaryDeclare and can participate in discussions on all topics
Robert RintoulPapworth Hospital NHS Trust acts as a reference centre for bronchoscopy equipment for Olympus KeyMed and as such are in receipt of loan equipment used for the diagnosis of lung cancer. Olympus KeyMed have also provided unrestricted educational grants to support annual endobronchial untrasound course.Non-personal pecuniary, specificDeclare and can participate in discussions on all topics
Matthew HattonAdvisory Board Consultancy fee received from GSK. Travel bursary to attend ASCO conference 2008 from RochePersonal pecuniary, specificDeclare and must withdraw from discussions on all topics that include GSK and Roche interventions
Michael PeakeFellow of the RCP and RCR. Member of NCRI Lung cancer Clinical Research Group and member of the British Thoracic Oncology Group Steering CommitteePersonal non-pecuniaryDeclare and can participate in discussions on all topics
American Society of Clinical Oncology (ASCO), Chicago. Grant to cover travel plus registration and accommodation. RochePersonal pecuniary, non-specificDeclare and can participate in discussions
World Lung Cancer Conference, Seoul, Korea. Grant to cover travel plus registration and accommodation. RochePersonal pecuniary, non-specificDeclare and can participate in discussions on all topics as the expenses were not beyond reasonable amounts
British Thoracic Society Winter Meeting, London. Registration fee and accommodtaion. Boehringer Igelheim LtdPersonal pecuniary, non-specificDeclare and can participate in discussions on all topics as the expenses were not beyond reasonable amounts
British Thoracic Oncology Group Annual Meeting, Dublin. Grant towards travel and accommodation. Eli lilly & CoPersonal pecuniary, non-specificDeclare and can participate in discussions on all topics as the expenses were not beyond reasonable amounts
American Society for Clinical Oncology Annual Meeting, Chicago. Grant towards travel, accommodation and registration. RochePersonal pecuniary, non-specificDeclare and can participate in discussions on all topics as the expenses were not beyond reasonable amounts
European Respiratory Society Annual Meeting, Berlin. Travel grant plus registration and accommodation. Boehringer Igelheim LtdPersonal pecuniary, non-specificDeclare and can participate in discussions on all topics as the expenses were not beyond reasonable amounts
In the Institute for Lung Health in Leicester I run an annual 2 day educational course on lung cancer for which we receive sponsorship from Eli Lilly & Co, Pierre Fabre Oncology, Sanofi Aventis and Roche PharmaceuticalsPersonal pecuniary, non-specificDeclare and can participate in discussions on all topics as the expenses were not beyond reasonable amounts
Remunerated lectures:Personal pecuniary, specificDeclare and must withdraw from discussions on all topics that include Eli Lilly interventions
1. “The Lung Cancer and Mesothelioma Advisory Group and the Cancer Reform Strategy. The practical management of thoracic cancers, British Library, London, 21st November 2007 Sponsored by Eli Lilly – title and content chosen entirely by myself.
2. “The value of second line chemotherapy in Small Cell Lung Cancer.” British Thoracic Oncology Group National Conference on Small Cell Lung Cancer. Christie Hospital, Manchester, 25th September 2008. Speaker fee covered by a grant from GSK pharmaceuticals. Title and content chosen entirely by myself and an independent conference organising group.Personal pecuniary, specificDeclare and must withdraw from discussions on all topics that include GSK interventions
Advisory Board for Roche Pharmaceuticals, ManchesterPersonal pecuniary, specificDeclare and must withdraw from discussions on all topics that include Roche interventions
Advisory Board for Roche Pharmaceuticals, CambridgePersonal pecuniary, specificDeclare and must withdraw from discussions on all topics that include Roche interventions
Advice to GSK regarding health economics of lung cancerPersonal pecuniary, specificDeclare and must withdraw from discussions on all topics that include GSK interventions
Advice to Pfizer Ltd regarding health economics of lung cancerPersonal pecuniary, specificDeclare and must withdraw from discussions on all topics that include Pfizer interventions
Advisory Board for Astra Zeneca pharmaceuticalsPersonal pecuniary, specificDeclare and must withdraw from discussions on all topics that include AstraZeneca interventions
1

Afatinib was not included in any of the topics investigated by the guideline and was therefore not discussed by the GDG

Members of the Guideline Development Group (GDG) 2005

GDG Chair
Dr Jesme Baird (Chair)Director of Patient Care, The Roy Castle Lung Cancer Foundation; patient representative
Group Members
Ms Caroline Belchamber*Senior Oncology Physiotherapist, Poole Hospital, Dorset; Chartered Society of Physiotherapy
Dr David BellamyGeneral Practitioner, Bournemouth, Dorset; Standing Committee of General Practitioners, Royal College of Physicians, London
Ms Denise BlakeLead Pharmacist, North London Cancer Network, and Chair British Oncology Pharmacy Association; Royal Pharmaceutical Society of Great Britain
Dr Colin ClellandConsultant Pathologist, John Radcliffe Hospital, Oxford; Royal College of Pathologists
Dr Dennis ErautConsultant Chest Physician, Southend Hospital, Essex; British Thoracic Society
Dr Fergus GleesonConsultant Radiologist, Churchill Hospital, Oxford; Royal College of Radiologists
Dr Peter HarveyConsultant Clinical Psychologist, St James's University Hospital, Leeds; British Psychosocial Oncology Society
Ms Patricia HuntPalliative Care Nurse Specialist – Lung Cancer, Royal Marsden Hospital, London; Royal College of Nursing
Ms Barbara LeungClinical Nurse Specialist – Lung Cancer, Birmingham, Heartlands Hospital; Royal College of Nursing
Ms Katherine Malholtra*Superintendent Physiotherapist, Royal Marsden Hospital, London; Chartered Society of Physiotherapy
Ms Theresa MannFormerly Cancer Support Service Specialist Nurse, CancerBACUP; patient representative
Ms Maureen McPakeLecturer in Radiotherapy, Glasgow Caledonian University; Society of Radiographers
Ms Catriona MooreCancer Support Service Specialist Nurse, CancerBACUP; patient representative
Dr Martin MuersConsultant Physician, The General Infirmary at Leeds; British Thoracic Society
Dr Mike O'DohertySenior Lecturer in Imaging Sciences, Guys, Kings and St Thomas' School of Medicine, and Consultant in Nuclear Medicine, Guy's and St Thomas' NHS Foundation Trust, London; British Nuclear Medicine Society
Dr Nick RowellClinical Oncologist, Maidstone Hospital, Kent; Royal College of Radiologists, Faculty of Clinical Oncology, and Cochrane Lung Cancer Group
Ms Denise SilveyClinical Nurse Specialist – Lung Cancer, Birmingham Heartlands Hospital; Royal College of Nursing
Dr Colin SinclairConsultant Anaesthetist, Cardiothoracic Surgery, Royal Infirmary of Edinburgh; Royal College of Anaesthetists
Mr Peter TebbitNational Policy Adviser, National Council for Hospice and Specialist Palliative Care
Professor Tom TreasureConsultant Thoracic Surgeon, Guy's and St Thomas' Hospital, London; Society of Cardiothoracic Surgeons
Dr Andrew WilcockReader and Consultant in Palliative Medicine and Medical Oncology, Royal College of Physicians Clinical Effectiveness Unit
Ms Judy Williams*Senior Physiotherapist, Poole Hospital, Dorset; Chartered Society of Physiotherapy
Professor Penella WollConsultant Medical Oncologist, Weston Park Hospital, Sheffield; Royal College of Physicians
*

Shared seat on Guideline Development Group

Shared seat on Guideline Development Group

Conflict of Interests

The Guideline Development Group were asked to declare any possible conflict of interest and none that could interfere with their work on the guideline were declared. All documentation is held by the National Collaborating Centre for Acute Care.

November 2008 – June 2009

Afatinib was not included in any of the topics investigated by the guideline and was therefore not discussed by the GDG

Shared seat on Guideline Development Group

Shared seat on Guideline Development Group

Copyright © 2011, National Collaborating Centre for Cancer.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licenses issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

Bookshelf ID: NBK99029
PubReader format: click here to try

Views

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...